Traws Pharma preps revised toxicology data for MHRA resubmission by Q3 2026
The company plans to resubmit an updated toxicology package for tivoxavir marboxil after MHRA feedback, aiming to support a Phase 2a influenza Challenge study.
SEC filing
Latest
3 stories
Friday, August 14
Friday, July 10
Traws Pharma files prospectus supplement for up to $5.58 million at-the-market stock sale
The company disclosed a clinical hold on its bird flu drug and a going concern warning while setting terms for a Citizens Capital Markets equity sale program.
SEC filing
Thursday, July 9
Traws Pharma stockholders approve share increase, elect directors at annual meeting
At its July 8, 2026 annual meeting, Traws Pharma stockholders approved a 2,000,000-share increase to the company's incentive compensation plan and elected seven directors.
SEC filing